Preston Klassen
2011 - Orexigen Therapeutics
In 2011, Preston Klassen earned a total compensation of $2.1M as Head of Global NB32 Program and Senior Vice President, Product Development at Orexigen Therapeutics, a 111% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $259,000 |
|---|---|
| Option Awards | $1,440,066 |
| Salary | $370,000 |
| Other | $72,120 |
| Total | $2,141,186 |
Klassen received $1.4M in option awards, accounting for 67% of the total pay in 2011.
Klassen also received $259K in non-equity incentive plan, $370K in salary and $72.1K in other compensation.
Rankings
In 2011, Preston Klassen's compensation ranked 3,084th out of 10,747 executives tracked by ExecPay. In other words, Klassen earned more than 71.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,084 out of 10,747 | 71st |
Division Manufacturing | 1,071 out of 3,960 | 73rd |
Major group Chemicals And Allied Products | 214 out of 1,033 | 79th |
Industry group Drugs | 119 out of 781 | 85th |
Industry Pharmaceutical Preparations | 100 out of 571 | 83rd |
Source: SEC filing on April 30, 2014.
Klassen's colleagues
We found five more compensation records of executives who worked with Preston Klassen at Orexigen Therapeutics in 2011.
2011
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2011
Heather Turner
Orexigen Therapeutics
General Counsel
2011
Joseph Hagan
Orexigen Therapeutics
Chief Business Officer
2011
Mark Booth
Orexigen Therapeutics
Chief Commercial Officer
2011
Graham Cooper
Orexigen Therapeutics